Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

被引：0
|
作者：
Gianni, Caterina [1 ]
Nicolo, Eleonora [2 ]
Cristofanilli, Massimo [2 ]
机构：
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Breast & GYN Unit, Meldola, Italy
[2] Weill Cornell Med, Div Hematol Oncol, Dept Med, 1300 York Ave, New York, NY 10065 USA
来源：
TRANSLATIONAL BREAST CANCER RESEARCH | 2024年 / 5卷
关键词：
CDK4/6; inhibitors; early breast cancer (EBC); ribociclib; hormone receptor positive (HR+); PLUS ENDOCRINE THERAPY; PALBOCICLIB;
D O I：
10.21037/tbcr-24-41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
    April C. Watt
    Shom Goel
    Breast Cancer Research, 24
  • [22] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [23] Common AEs associated with CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
    Yardley, Denise A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [24] Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
    Mohammadhadi Khorrami
    Vidya Sakar Viswanathan
    Priyanka Reddy
    Nathaniel Braman
    Siddharth Kunte
    Amit Gupta
    Jame Abraham
    Alberto J. Montero
    Anant Madabhushi
    npj Breast Cancer, 9
  • [25] Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
    Khorrami, Mohammadhadi
    Viswanathan, Vidya Sakar
    Reddy, Priyanka
    Braman, Nathaniel
    Kunte, Siddharth
    Gupta, Amit
    Abraham, Jame
    Montero, Alberto J.
    Madabhushi, Anant
    NPJ BREAST CANCER, 2023, 9 (01)
  • [26] CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
    Agostinetto, E.
    Vian, L.
    Caparica, R.
    Bruzzone, M.
    Ceppi, M.
    Lambertini, M.
    Ponde, N.
    de Azambuja, E.
    ESMO OPEN, 2021, 6 (02)
  • [27] ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
    Matikas, A.
    Lambertini, M.
    ESMO OPEN, 2021, 6 (01)
  • [28] Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
    Jamie O. Brett
    Paige E. Herman
    Erica L. Mayer
    Aditya Bardia
    Seth A. Wander
    Current Breast Cancer Reports, 2022, 14 : 222 - 232
  • [29] Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
    Herrera-Abreu, Maria Teresa
    Palafox, Marta
    Asghar, Uzma
    Rivas, Martin A.
    Cutts, Rosalind J.
    Garcia-Murillas, Isaac
    Pearson, Alex
    Guzman, Marta
    Rodriguez, Olga
    Grueso, Judit
    Bellet, Meritxell
    Cortes, Javier
    Elliott, Richard
    Pancholi, Sunil
    Baselga, Jose
    Dowsett, Mitch
    Martin, Lesley-Ann
    Turner, Nicholas C.
    Serra, Violeta
    CANCER RESEARCH, 2016, 76 (08) : 2301 - 2313
  • [30] Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer
    Witkiewicz, Agnieszka
    CANCER RESEARCH, 2023, 83 (05)
12345